APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical Formulation Development Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmaceutical Formulation Development Service Market Outlook and Growth Opportunities 2026

Report ID 174214350421 December 2025209 pages

Choose your research edition.

Industry ResearchPharmaceutical Formulation Development Service Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical Formulation Development Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Pharmaceutical Formulation Development Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical Formulation Development Service Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical Formulation Development Service Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Pharmaceutical Formulation Development Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmaceutical Formulation Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmaceutical Formulation Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmaceutical Formulation Development Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmaceutical Formulation Development Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmaceutical Formulation Development Service market include Adragos Pharma, Agno Pharma, Ascendia Pharmaceutical Solutions, Aurigene Pharmaceutical Services, Avivia, CMC Pharmaceuticals, Coriolis Pharma, Crystal Pharmatech and Eoltinplas Pharmaceutical Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pharmaceutical Formulation Development Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmaceutical Formulation Development Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmaceutical Formulation Development Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmaceutical Formulation Development Service market.

Pharmaceutical Formulation Development Service Segment by Company

Adragos Pharma

Agno Pharma

Ascendia Pharmaceutical Solutions

Aurigene Pharmaceutical Services

Avivia

CMC Pharmaceuticals

Coriolis Pharma

Crystal Pharmatech

Eoltinplas Pharmaceutical Company

Intertek

LGM Pharma

Lonza

Lucideon

Scantox

Suven Pharma

Seda

Sharp Services

Kemwell Pharma

Pharmaceutical Formulation Development Service Segment by Type

Poorly Soluble Drug Development Service

Highly Permeable Drug Development Service

Peptide/Protein Drug Development Service

High-Dose Drug Development Service

Pharmaceutical Formulation Development Service Segment by Application

Innovative Drug R&D Companies

Generic Drug Companies

Improved New Drug Companies

Pharmaceutical Formulation Development Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmaceutical Formulation Development Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmaceutical Formulation Development Service key companies, revenue, market share, and recent developments.

3. To split the Pharmaceutical Formulation Development Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmaceutical Formulation Development Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmaceutical Formulation Development Service significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmaceutical Formulation Development Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Formulation Development Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Formulation Development Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Formulation Development Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical Formulation Development Service industry.

Chapter 3: Detailed analysis of Pharmaceutical Formulation Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmaceutical Formulation Development Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmaceutical Formulation Development Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmaceutical Formulation Development Service Industry Trends Table 2. Pharmaceutical Formulation Development Service Industry Drivers Table 3. Pharmaceutical Formulation Development Service Industry Opportunities and Challenges Table 4. Pharmaceutical Formulation Development Service Industry Restraints Table 5. Global Pharmaceutical Formulation Development Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmaceutical Formulation Development Service Revenue Share by Company (2021-2026) Table 7. Global Pharmaceutical Formulation Development Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmaceutical Formulation Development Service Key Company Manufacturing Base & Headquarters Table 9. Global Pharmaceutical Formulation Development Service Company, Product Type & Application Table 10. Global Pharmaceutical Formulation Development Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmaceutical Formulation Development Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Poorly Soluble Drug Development Service Table 15. Significant Companies of Highly Permeable Drug Development Service Table 16. Significant Companies of Peptide/Protein Drug Development Service Table 17. Significant Companies of High-Dose Drug Development Service Table 18. Global Pharmaceutical Formulation Development Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pharmaceutical Formulation Development Service Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pharmaceutical Formulation Development Service Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pharmaceutical Formulation Development Service Sales Value Share by Type (2021-2026) Table 22. Global Pharmaceutical Formulation Development Service Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Innovative Drug R&D Companies Table 24. Significant Companies of Generic Drug Companies Table 25. Significant Companies of Improved New Drug Companies Table 26. Global Pharmaceutical Formulation Development Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pharmaceutical Formulation Development Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Pharmaceutical Formulation Development Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Pharmaceutical Formulation Development Service Sales Value Share by Application (2021-2026) Table 30. Global Pharmaceutical Formulation Development Service Sales Value Share by Application (2027-2032) Table 31. Global Pharmaceutical Formulation Development Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pharmaceutical Formulation Development Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Pharmaceutical Formulation Development Service Sales Value Share by Region (2021-2026) Table 34. Global Pharmaceutical Formulation Development Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Pharmaceutical Formulation Development Service Sales Value Share by Region (2027-2032) Table 36. Global Pharmaceutical Formulation Development Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pharmaceutical Formulation Development Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Pharmaceutical Formulation Development Service Sales Value Market Share by Country (2021-2026) Table 39. Global Pharmaceutical Formulation Development Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Pharmaceutical Formulation Development Service Sales Value Market Share by Country (2027-2032) Table 41. Adragos Pharma Company Information Table 42. Adragos Pharma Business Overview Table 43. Adragos Pharma Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Adragos Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 45. Adragos Pharma Recent Development Table 46. Agno Pharma Company Information Table 47. Agno Pharma Business Overview Table 48. Agno Pharma Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Agno Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 50. Agno Pharma Recent Development Table 51. Ascendia Pharmaceutical Solutions Company Information Table 52. Ascendia Pharmaceutical Solutions Business Overview Table 53. Ascendia Pharmaceutical Solutions Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Ascendia Pharmaceutical Solutions Pharmaceutical Formulation Development Service Product Portfolio Table 55. Ascendia Pharmaceutical Solutions Recent Development Table 56. Aurigene Pharmaceutical Services Company Information Table 57. Aurigene Pharmaceutical Services Business Overview Table 58. Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Service Product Portfolio Table 60. Aurigene Pharmaceutical Services Recent Development Table 61. Avivia Company Information Table 62. Avivia Business Overview Table 63. Avivia Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Avivia Pharmaceutical Formulation Development Service Product Portfolio Table 65. Avivia Recent Development Table 66. CMC Pharmaceuticals Company Information Table 67. CMC Pharmaceuticals Business Overview Table 68. CMC Pharmaceuticals Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. CMC Pharmaceuticals Pharmaceutical Formulation Development Service Product Portfolio Table 70. CMC Pharmaceuticals Recent Development Table 71. Coriolis Pharma Company Information Table 72. Coriolis Pharma Business Overview Table 73. Coriolis Pharma Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Coriolis Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 75. Coriolis Pharma Recent Development Table 76. Crystal Pharmatech Company Information Table 77. Crystal Pharmatech Business Overview Table 78. Crystal Pharmatech Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Crystal Pharmatech Pharmaceutical Formulation Development Service Product Portfolio Table 80. Crystal Pharmatech Recent Development Table 81. Eoltinplas Pharmaceutical Company Company Information Table 82. Eoltinplas Pharmaceutical Company Business Overview Table 83. Eoltinplas Pharmaceutical Company Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eoltinplas Pharmaceutical Company Pharmaceutical Formulation Development Service Product Portfolio Table 85. Eoltinplas Pharmaceutical Company Recent Development Table 86. Intertek Company Information Table 87. Intertek Business Overview Table 88. Intertek Pharmaceutical Formulation Development Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Intertek Pharmaceutical Formulation Development Service Product Portfolio Table 90. Intertek Recent Development Table 91. LGM Pharma Company Information Table 92. LGM Pharma Business Overview Table 93. LGM Pharma Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. LGM Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 95. LGM Pharma Recent Development Table 96. Lonza Company Information Table 97. Lonza Business Overview Table 98. Lonza Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Lonza Pharmaceutical Formulation Development Service Product Portfolio Table 100. Lonza Recent Development Table 101. Lucideon Company Information Table 102. Lucideon Business Overview Table 103. Lucideon Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Lucideon Pharmaceutical Formulation Development Service Product Portfolio Table 105. Lucideon Recent Development Table 106. Scantox Company Information Table 107. Scantox Business Overview Table 108. Scantox Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Scantox Pharmaceutical Formulation Development Service Product Portfolio Table 110. Scantox Recent Development Table 111. Suven Pharma Company Information Table 112. Suven Pharma Business Overview Table 113. Suven Pharma Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Suven Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 115. Suven Pharma Recent Development Table 116. Seda Company Information Table 117. Seda Business Overview Table 118. Seda Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Seda Pharmaceutical Formulation Development Service Product Portfolio Table 120. Seda Recent Development Table 121. Sharp Services Company Information Table 122. Sharp Services Business Overview Table 123. Sharp Services Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Sharp Services Pharmaceutical Formulation Development Service Product Portfolio Table 125. Sharp Services Recent Development Table 126. Kemwell Pharma Company Information Table 127. Kemwell Pharma Business Overview Table 128. Kemwell Pharma Pharmaceutical Formulation Development Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Kemwell Pharma Pharmaceutical Formulation Development Service Product Portfolio Table 130. Kemwell Pharma Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Pharmaceutical Formulation Development Service Product Image Figure 2. Global Pharmaceutical Formulation Development Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical Formulation Development Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmaceutical Formulation Development Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Poorly Soluble Drug Development Service Image Figure 8. Highly Permeable Drug Development Service Image Figure 9. Peptide/Protein Drug Development Service Image Figure 10. High-Dose Drug Development Service Image Figure 11. Global Pharmaceutical Formulation Development Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pharmaceutical Formulation Development Service Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pharmaceutical Formulation Development Service Sales Value Share by Type (2021-2032) Figure 14. Innovative Drug R&D Companies Image Figure 15. Generic Drug Companies Image Figure 16. Improved New Drug Companies Image Figure 17. Global Pharmaceutical Formulation Development Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pharmaceutical Formulation Development Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pharmaceutical Formulation Development Service Sales Value Share by Application (2021-2032) Figure 20. Global Pharmaceutical Formulation Development Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Pharmaceutical Formulation Development Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Pharmaceutical Formulation Development Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America Pharmaceutical Formulation Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Pharmaceutical Formulation Development Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Pharmaceutical Formulation Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Pharmaceutical Formulation Development Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Pharmaceutical Formulation Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Pharmaceutical Formulation Development Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America Pharmaceutical Formulation Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Pharmaceutical Formulation Development Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Pharmaceutical Formulation Development Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Poorly Soluble Drug Development Service
  • Highly Permeable Drug Development Service
  • Peptide/Protein Drug Development Service
  • High-Dose Drug Development Service
Applications
  • Innovative Drug R&D Companies
  • Generic Drug Companies
  • Improved New Drug Companies
Companies covered
  • Adragos Pharma
  • Agno Pharma
  • Ascendia Pharmaceutical Solutions
  • Aurigene Pharmaceutical Services
  • Avivia
  • CMC Pharmaceuticals
  • Coriolis Pharma
  • Crystal Pharmatech
  • Eoltinplas Pharmaceutical Company
  • Intertek
  • LGM Pharma
  • Lonza
  • Lucideon
  • Scantox
  • Suven Pharma
  • Seda
  • Sharp Services
  • Kemwell Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmaceutical Formulation Development Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmaceutical Formulation Development Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmaceutical Formulation Development Service Market Dynamics
  1. 2.1 Pharmaceutical Formulation Development Service Industry Trends
  2. 2.2 Pharmaceutical Formulation Development Service Industry Drivers
  3. 2.3 Pharmaceutical Formulation Development Service Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical Formulation Development Service Industry Restraints
3 Pharmaceutical Formulation Development Service Market by Company
  1. 3.1 Global Pharmaceutical Formulation Development Service Company Revenue Ranking in 2025
  2. 3.2 Global Pharmaceutical Formulation Development Service Revenue by Company (2021-2026)
  3. 3.3 Global Pharmaceutical Formulation Development Service Company Ranking (2024-2026)
  4. 3.4 Global Pharmaceutical Formulation Development Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmaceutical Formulation Development Service Company Product Type and Application
  6. 3.6 Global Pharmaceutical Formulation Development Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmaceutical Formulation Development Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmaceutical Formulation Development Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmaceutical Formulation Development Service Market by Type
  1. 4.1 Pharmaceutical Formulation Development Service Type Introduction
  2. 4.1.1 Poorly Soluble Drug Development Service
  3. 4.1.2 Highly Permeable Drug Development Service
  4. 4.1.3 Peptide/Protein Drug Development Service
  5. 4.1.4 High-Dose Drug Development Service
  6. 4.2 Global Pharmaceutical Formulation Development Service Sales Value by Type
  7. 4.2.1 Global Pharmaceutical Formulation Development Service Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pharmaceutical Formulation Development Service Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pharmaceutical Formulation Development Service Sales Value Share by Type (2021-2032)
5 Pharmaceutical Formulation Development Service Market by Application
  1. 5.1 Pharmaceutical Formulation Development Service Application Introduction
  2. 5.1.1 Innovative Drug R&D Companies
  3. 5.1.2 Generic Drug Companies
  4. 5.1.3 Improved New Drug Companies
  5. 5.2 Global Pharmaceutical Formulation Development Service Sales Value by Application
  6. 5.2.1 Global Pharmaceutical Formulation Development Service Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pharmaceutical Formulation Development Service Sales Value by Application (2021-2032)
  8. 5.2.3 Global Pharmaceutical Formulation Development Service Sales Value Share by Application (2021-2032)
6 Pharmaceutical Formulation Development Service Regional Value Analysis
  1. 6.1 Global Pharmaceutical Formulation Development Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmaceutical Formulation Development Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmaceutical Formulation Development Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmaceutical Formulation Development Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmaceutical Formulation Development Service Sales Value (2021-2032)
  7. 6.3.2 North America Pharmaceutical Formulation Development Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmaceutical Formulation Development Service Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmaceutical Formulation Development Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmaceutical Formulation Development Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmaceutical Formulation Development Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmaceutical Formulation Development Service Sales Value (2021-2032)
  16. 6.6.2 South America Pharmaceutical Formulation Development Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmaceutical Formulation Development Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmaceutical Formulation Development Service Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical Formulation Development Service Country-level Value Analysis
  1. 7.1 Global Pharmaceutical Formulation Development Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmaceutical Formulation Development Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmaceutical Formulation Development Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmaceutical Formulation Development Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmaceutical Formulation Development Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmaceutical Formulation Development Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmaceutical Formulation Development Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adragos Pharma
  2. 8.1.1 Adragos Pharma Company Information
  3. 8.1.2 Adragos Pharma Business Overview
  4. 8.1.3 Adragos Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Adragos Pharma Pharmaceutical Formulation Development Service Product Portfolio
  6. 8.1.5 Adragos Pharma Recent Developments
  7. 8.2 Agno Pharma
  8. 8.2.1 Agno Pharma Company Information
  9. 8.2.2 Agno Pharma Business Overview
  10. 8.2.3 Agno Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Agno Pharma Pharmaceutical Formulation Development Service Product Portfolio
  12. 8.2.5 Agno Pharma Recent Developments
  13. 8.3 Ascendia Pharmaceutical Solutions
  14. 8.3.1 Ascendia Pharmaceutical Solutions Company Information
  15. 8.3.2 Ascendia Pharmaceutical Solutions Business Overview
  16. 8.3.3 Ascendia Pharmaceutical Solutions Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ascendia Pharmaceutical Solutions Pharmaceutical Formulation Development Service Product Portfolio
  18. 8.3.5 Ascendia Pharmaceutical Solutions Recent Developments
  19. 8.4 Aurigene Pharmaceutical Services
  20. 8.4.1 Aurigene Pharmaceutical Services Company Information
  21. 8.4.2 Aurigene Pharmaceutical Services Business Overview
  22. 8.4.3 Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aurigene Pharmaceutical Services Pharmaceutical Formulation Development Service Product Portfolio
  24. 8.4.5 Aurigene Pharmaceutical Services Recent Developments
  25. 8.5 Avivia
  26. 8.5.1 Avivia Company Information
  27. 8.5.2 Avivia Business Overview
  28. 8.5.3 Avivia Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Avivia Pharmaceutical Formulation Development Service Product Portfolio
  30. 8.5.5 Avivia Recent Developments
  31. 8.6 CMC Pharmaceuticals
  32. 8.6.1 CMC Pharmaceuticals Company Information
  33. 8.6.2 CMC Pharmaceuticals Business Overview
  34. 8.6.3 CMC Pharmaceuticals Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CMC Pharmaceuticals Pharmaceutical Formulation Development Service Product Portfolio
  36. 8.6.5 CMC Pharmaceuticals Recent Developments
  37. 8.7 Coriolis Pharma
  38. 8.7.1 Coriolis Pharma Company Information
  39. 8.7.2 Coriolis Pharma Business Overview
  40. 8.7.3 Coriolis Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Coriolis Pharma Pharmaceutical Formulation Development Service Product Portfolio
  42. 8.7.5 Coriolis Pharma Recent Developments
  43. 8.8 Crystal Pharmatech
  44. 8.8.1 Crystal Pharmatech Company Information
  45. 8.8.2 Crystal Pharmatech Business Overview
  46. 8.8.3 Crystal Pharmatech Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Crystal Pharmatech Pharmaceutical Formulation Development Service Product Portfolio
  48. 8.8.5 Crystal Pharmatech Recent Developments
  49. 8.9 Eoltinplas Pharmaceutical Company
  50. 8.9.1 Eoltinplas Pharmaceutical Company Company Information
  51. 8.9.2 Eoltinplas Pharmaceutical Company Business Overview
  52. 8.9.3 Eoltinplas Pharmaceutical Company Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eoltinplas Pharmaceutical Company Pharmaceutical Formulation Development Service Product Portfolio
  54. 8.9.5 Eoltinplas Pharmaceutical Company Recent Developments
  55. 8.10 Intertek
  56. 8.10.1 Intertek Company Information
  57. 8.10.2 Intertek Business Overview
  58. 8.10.3 Intertek Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Intertek Pharmaceutical Formulation Development Service Product Portfolio
  60. 8.10.5 Intertek Recent Developments
  61. 8.11 LGM Pharma
  62. 8.11.1 LGM Pharma Company Information
  63. 8.11.2 LGM Pharma Business Overview
  64. 8.11.3 LGM Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 LGM Pharma Pharmaceutical Formulation Development Service Product Portfolio
  66. 8.11.5 LGM Pharma Recent Developments
  67. 8.12 Lonza
  68. 8.12.1 Lonza Company Information
  69. 8.12.2 Lonza Business Overview
  70. 8.12.3 Lonza Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lonza Pharmaceutical Formulation Development Service Product Portfolio
  72. 8.12.5 Lonza Recent Developments
  73. 8.13 Lucideon
  74. 8.13.1 Lucideon Company Information
  75. 8.13.2 Lucideon Business Overview
  76. 8.13.3 Lucideon Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lucideon Pharmaceutical Formulation Development Service Product Portfolio
  78. 8.13.5 Lucideon Recent Developments
  79. 8.14 Scantox
  80. 8.14.1 Scantox Company Information
  81. 8.14.2 Scantox Business Overview
  82. 8.14.3 Scantox Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Scantox Pharmaceutical Formulation Development Service Product Portfolio
  84. 8.14.5 Scantox Recent Developments
  85. 8.15 Suven Pharma
  86. 8.15.1 Suven Pharma Company Information
  87. 8.15.2 Suven Pharma Business Overview
  88. 8.15.3 Suven Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Suven Pharma Pharmaceutical Formulation Development Service Product Portfolio
  90. 8.15.5 Suven Pharma Recent Developments
  91. 8.16 Seda
  92. 8.16.1 Seda Company Information
  93. 8.16.2 Seda Business Overview
  94. 8.16.3 Seda Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Seda Pharmaceutical Formulation Development Service Product Portfolio
  96. 8.16.5 Seda Recent Developments
  97. 8.17 Sharp Services
  98. 8.17.1 Sharp Services Company Information
  99. 8.17.2 Sharp Services Business Overview
  100. 8.17.3 Sharp Services Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sharp Services Pharmaceutical Formulation Development Service Product Portfolio
  102. 8.17.5 Sharp Services Recent Developments
  103. 8.18 Kemwell Pharma
  104. 8.18.1 Kemwell Pharma Company Information
  105. 8.18.2 Kemwell Pharma Business Overview
  106. 8.18.3 Kemwell Pharma Pharmaceutical Formulation Development Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Kemwell Pharma Pharmaceutical Formulation Development Service Product Portfolio
  108. 8.18.5 Kemwell Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst